Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure
University of Virginia Health System · University of Virginia · +7 more institutions
Abstract
Obesity is a known risk factor for heart failure with preserved ejection fraction (HFpEF) and is considered a distinct phenotype with more concentric remodeling. Epicardial adipose tissue (EAT) is also increased in obesity-related HFpEF and is associated with adverse events.
The cardiac magnetic resonance (CMR) substudy of the SUMMIT trial aimed to examine the effects of tirzepatide on cardiac structure and function with the underlying hypothesis that it would reduce left ventricular (LV) mass and EAT in obesity-related HFpEF.
Citation impact
- FWCI
- 49.60
- Percentile
- 100%
- References
- 26
Authors
11- CMChristopher M. KramerCorresponding
University of Virginia Health System, University of Virginia
- BABarry A. Borlaug
Mayo Clinic, Mayo Clinic in Arizona
- MRMichael R. Zile
Medical University of South Carolina
- DRDustin Ruff
Eli Lilly (United States)
- JMJoseph M DiMaria
University of Virginia Health System, University of Virginia
Topics & keywords
- Medicine
- Adipose tissue
- Heart failure
- Cardiology
- Obesity
- Internal medicine
- Fat mass